EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[°ËÁø FAQ]

[2017-3-6. ¾Öµ¶ÀÚ Áú¹®]

¾È³çÇϽʴϱî? Àú´Â ºÎ»ê¿¡ ÀÖ´Â 2Â÷º´¿ø¿¡¼­ Áø·á¸¦ º¸°í ÀÖ´Â ºÀÁ÷ÀÇ ÀÔ´Ï´Ù. Ç×»ó EndoTODAY º¸´Â °ÍÀÌ Ãâ±Ù ÈÄ Á¦ÀÏ Ã³À½ ÇÏ´Â (ȸÁøº¸´Ù ¸ÕÀú^^) ÀÏÀÏ Á¤µµ·Î ¸¹Àº µµ¿ò°ú ÃʽÉ, ¿­Á¤À» ¹è¿ì°í ÀÖ½À´Ï´Ù.

¿ì¸®³ª¶ó¿¡¼­´Â 50¼¼ ºÎÅÍ ºÐº¯ °Ë»ç¸¦ Çϵµ·Ï ÇÏ°í ÀÖ½À´Ï´Ù. ¹°·Ð ºÐº¯ÀáÇ÷°Ë»ç °á°ú°¡ ±¦Âú´Ù°í ´Ù ±¦ÂúÀº °ÍÀº ¾Æ´Ï´Ù´Â °ÍÀ» ȯÀڵ鿡°Ô °­Á¶ÇÏ°í ÀÖ½À´Ï´Ù¸¸, ¸¹Àº ȯÀÚ ºÐµéÀÌ ºÐº¯ÀáÇ÷°Ë»ç¿¡ ¿ÀÇظ¦ ÇÏ°í ÀÖ´Â °Í °°½À´Ï´Ù. ÃÖ±Ù ÇÑ ´Þ »çÀÌ¿¡ 21¼¼ ±ºÀÎ, 32¼¼ ¼±»ý´Ô, 33¼¼ Á÷ÀåÀÎ µÎ ºÐ µî ÀþÀº ¿¬·É¿¡¼­ Å« »çÀÌÁîÀÇ adenoma °¡ ¹ß°ßµÇ¾î ȯÀÚµéÀÌ "±×·³ µµ´ëü ¸î »ìºÎÅÍ ´ëÀå³»½Ã°æÀ» ¹Þ¾Æ¾ß Çմϱî?"¶ó°í ¹°¾îº¾´Ï´Ù. ÀÌ·± °æ¿ì ±³¼ö´Ô²²¼­´Â ¾î¶»°Ô ´ë´äÀ» ÇϽôÂÁö¿ä?

Ç×»ó °Ç°­ÇϽðí Àúµµ ±³¼ö´Ô²²¼­ °­Á¶ÇϽô ¹Ù¸¥ ³»½Ã°æÀ» Çϵµ·Ï ¿­½ÉÈ÷ ³ë·ÂÇÏ°Ú½À´Ï´Ù.

[2017-3-8. ÀÌÁØÇà ´äº¯]

¿À·¡ Àü ¹«Áõ»ó ¿ª·ù¼º ½Äµµ¿°¿¡ ´ëÇÏ¿© ³íÀÇÇϸ鼭 ÇÑ ±³¼ö´Ô²²¼­ ¾Æ·¡¿Í °°Àº ¸ÞÀÏÀ» Áּż­ Å« ¿ï¸²ÀÌ ÀÖ¾ú½À´Ï´Ù (EndoTODAY 20131111).

"¹®Á¦´Â ÀÌ·ÐÀûÀ¸·Î´Â Ÿ´çÇÏ°ÚÁö¸¸, Àΰ£ÀÌ Àΰ£°ú »óÈ£ÀÛ¿ëÇÏ´Â »çȸ¶ó´Â °ø°£ÀÌ Á÷¼±ÀûÀÎ ³í¸®¸¸À¸·Î ¿òÁ÷ÀÌ´Â °ÍÀÌ ¾Æ´Ï¸ç ³í¸®º¸´Ù´Â ¿å¸Á°ú ÀÌ¿¡ ±â¹ÝÇÑ Á¤¼­°¡ ´õ Å« ÀÛ¿ëÀ» ÇÏ´Â ¶§°¡ ¸¹ÀºÁö¶ó ¼²ºÒ¸® ¹¹¶ó°í ¾ð±ÞÇϱ⵵ ¾î·Á¿î °Í °°½À´Ï´Ù. ÀÇÇп¡¼­ ÈçÈ÷ ÀÌ¿ëµÇ´Â Evidence¶õ Åë°èÀû ±Í³³¹ý¿¡ ±â¹ÝÇÑ evidence¸¦ À̾߱â Çϴµ¥ ÀÌ·± Evidence°¡ ¾øÀ» ¶§´Â ±âÁ¸ Áö½Ä¿¡ ±â¹ÝÇÑ ¿¬¿ªÀû »ç°í·Î ¹®Á¦¸¦ Ç® ¼ö ¹Û¿¡ ¾øÀ» °Í °°´Ù´Â »ý°¢À» ÇÕ´Ï´Ù. ¹°·Ð ƯÁ¤ »ç¾È¿¡ ´ëÇÑ Evidence¸¦ ¸¸µé±â À§ÇÑ ³ë·ÂÀ» °ÔÀ»¸® ÇÏÁö ¸»¾Æ¾ß ÇÏ°ÚÁö¸¸¿ä."

Á¦°¡ ¾Öµ¶ÀÚ ÆíÁö¸¦ ±æ°Ô ÀοëÇÑ °ÍÀº ³í¸® ȤÀº evidence·Î "¿å¸Á°ú ÀÌ¿¡ ±â¹ÝÇÑ Á¤¼­"¸¦ ±Øº¹Çϱ⠾î·Æ´Ù´Â Á¡À» °­Á¶ÇÏ°í ½Í¾ú±â ¶§¹®ÀÔ´Ï´Ù. ¾Æ½Ã´Ù½ÃÇÇ °ËÁø(screening)ÀÌ ¸ðµç ¹®Á¦¸¦ ÇØ°áÇØ ÁÙ ¼ö ¾ø½À´Ï´Ù. °ËÁø °ü·Ã ºÎÀÛ¿ëÀ¸·Î »ç¸ÁÇϰųª Å« °í»ýÀ» ÇÏ´Â ºÐµéÀÌ »ý°¢º¸´Ù ÀûÁö ¾Ê½À´Ï´Ù. ¹ß°ßÇÒ ÇÊ¿ä°¡ ¾ø´Â »óȲÀÌ ³ëÃâµÇ¾î ºÒÇÊ¿äÇÑ °í¹ÎÀ¸·Î ¹ãÀ» ¼³Ä¡°Å³ª ºÒÇÊ¿äÇÑ Ä¡·á¸¦ ¹Þ´Â ºÐµéµµ ¾ÆÁÖ ¸¹½À´Ï´Ù. °ËÁøÀº ´ë±Ô¸ð ¿¬±¸¸¦ ÅëÇÏ¿© µæ°ú ½ÇÀ» Æò°¡ÇÑ ÀÚ·á°¡ ³ª¿À±â Àü±îÁö ¼²ºÒ¸® ±× È¿°ú¸¦ ´ÜÁ¤Çϱ⠾î·Á¿î ºÐ¾ßÀÔ´Ï´Ù. ºÒ¸íÈ®ÇÑ ¿µ¿ª¿¡ ´ëÇؼ­´Â °Ë»ç °á°ú¿¡ ÀÇÁ¸Çϱ⺸´Ù´Â °Ç°­ÇÑ ½Ä»ýÈ°°ú ÀûÀýÇÑ ¿îµ¿ µî »ýÈ° ½À°ü °ü¸®°¡ Áß¿äÇÒ ¼ö ÀÖ½À´Ï´Ù. »ó´çÇÑ ±Ù°Å°¡ Àְųª ÃÖ¼ÒÇÑ ÀÏÁ¤ ¼öÁØ ÀÌ»óÀÇ Å¸´ç¼ºÀ» °®´Â ºÐ¾ß¸¸ °ËÁøÀ» ¹Þ´Â °ÍÀÌ ÃÖ¼±ÀÏ °ÍÀÔ´Ï´Ù. ³ª¸ÓÁö´Â ¿î¸íÀ¸·Î ¹Þ¾Æµé¿©¾ßÁö¿ä. Àΰ£ÀÌ ¾î¶»°Ô ÇÒ ¼ö ¾ø´Â ºÐ¾ßµµ ÀÖ´Â ¹ýÀÔ´Ï´Ù. ´õ ÀßÇغ¸·Á´Ù°¡ ¸ÁÇÏ´Â ±×·± Àϵµ ÀÖ´Â ¹ýÀÔ´Ï´Ù.

¸»¾¸ÇϽŠ¹Ù¿Í °°ÀÌ ¾ÆÁÖ ÀþÀº ºÐµé¿¡¼­µµ °£È¤ Å« ¿ëÁ¾ÀÌ ¹ß°ßµÇ±âµµ ÇÕ´Ï´Ù. ¼Ò¾Æ¿¡¼­µµ ´ëÀå¾ÏÀÌ ¹ß°ßµÇ±âµµ ÇÕ´Ï´Ù. 10´ë À§¾ÏÀº Á¾Á¾ ÀÖ½À´Ï´Ù. ÀÌ·± ¸î ¸î »ç·Ê°¡ ÀÖ´Ù´Â ÀÌÀ¯·Î ¸ðµç »ç¶÷ÀÌ 10´ë¿¡ À§³»½Ã°æ, ´ëÀå³»½Ã°æÀ» ¹Þ¾Æ¾ß ÇÑ´Ù°í ÁÖÀåÇÒ ¼ö ¾ø½À´Ï´Ù. ºñ¿ë°ú ÇÕº´Áõ°ú »îÀÇ Áú ÀúÇÏ µîÀ» ¸ðµÎ °í·ÁÇØ¾ß Çϱ⠶§¹®ÀÔ´Ï´Ù.

±×·¯³ª ÀÌ¿Í °°Àº ³í¸® ȤÀº evidence°¡ Àΰ£ÀÇ "¿å¸Á"À» ±Øº¹ÇÒ ¼ö ¾ø´Ù´Â °ÍÀÌ ¹®Á¦ÀÔ´Ï´Ù. °Ô´Ù°¡ ¿ì¸®³ª¶ó¿¡¼­´Â °¡°Ý ¶ÇÇÑ ¸Å¿ì ½Î¼­ ÇÏ°Ú´Ù¸é ¸·±âµµ ¾î·Æ½À´Ï´Ù. °íµîÇлý, ´ëÇлý, À¯Çлý ȤÀº ÀþÀº ȸ»ç¿øµéÀÌ Á¤±âÀûÀ¸·Î °í°¡ÀÇ °ËÁøÀ» ¹Þ±âµµ Çϴµ¥... µµ¸®°¡ ¾ø½À´Ï´Ù. ¸»¸± ¼ö ¾ø½À´Ï´Ù. µæº¸´Ù ½ÇÀÌ ¸¹À» °ÍÀ̶ó´Â »ý°¢ÀÌ µé¾îµµ ¸»¸®±â ¾î·Æ½À´Ï´Ù. ±×°Ô ¿ì¸®³ª¶óÀÔ´Ï´Ù. ÀÇ»çÀÇ ±ÇÀ§°¡ ¸ÔÈ÷Áö ¾Ê´Â ³ª¶ó´Ï±î¿ä. ÁøÂû°ú ÀÇ»ç ó¹æµµ ¾øÀÌ ¾Æ¹«³ª ÀÇ·á±â°üÀ» ã¾Æ°¡ ´ëÀå³»½Ã°æÀ» ¹ÞÀ» ¼ö ÀÖ´Â ³ª¶ó´Â Àü ¼¼°è¿¡ ´ëÇѹα¹¹Û¿¡ ¾ø½À´Ï´Ù. ÀÌ°Ô ¸»À̳ª µË´Ï±î.

ÀþÀº »ç¶÷ÀÌ´õ¶óµµ Áõ»ó, °¡Á··Â, »ýÈ°½À°ü µîÀ» °í·ÁÇÏ¿© °ËÁø °¡À̵å¶óÀκ¸´Ù ¸î ³â ÀüºÎÅÍ °ËÁøÀ» ¹Þ´Â °ÍÀÌ Å¸´çÇÑ subgroupÀÌ ÀÖ½À´Ï´Ù. ±×µé¿¡°Ô´Â °Ë»ç¸¦ ±ÇÇÒ ¼ö ÀÖ°Ú½À´Ï´Ù. ±×·¯³ª ±× Á¤µµ°¡ ÃÖ¼±ÀÌ ¾Æ´Ò±î ÇÕ´Ï´Ù. ±× ÀÌ¿Ü¿¡´Â Àǻ簡 ¸ÕÀú ±ÇÇϱâ´Â ¾î·Æ½À´Ï´Ù. ÀþÀº »ç¶÷ÀÌ ±×³É °Ë»ç¸¦ ¹Þ¾Æ¼­ ¿îÁÁ°Ô Áß¿äÇÑ º´ÀÌ ¹ß°ßµÇ¾î ÀλýÀÌ ¹Ù²î´Â °æ¿ì°¡ ¾ø´Â °ÍÀº ¾Æ´Ï°ÚÁö¸¸, ±× ¹Ý´ëÀÇ °æ¿ìµµ ³Ê¹« ¸¹ÀÌ °æÇèÇÏ¿´½À´Ï´Ù. ºÒÇÊ¿äÇÑ °ËÁøÀ» ¹Þ´Ù°¡ Å« º´À» ¾òÀº »ç¶÷µµ ¾î·Ç º¸¾Ò½À´Ï´Ù. ÇѸ¶µð·Î µµ¹ÚÀÔ´Ï´Ù. Àǻ簡 µµ¹ÚÀ» ±ÇÇÒ ¼ö´Â ¾ø´Â ÀÏÀÔ´Ï´Ù.

Àú °°À¸¸é ÀÌ·¸°Ô ¸»¾¸µå¸± °Í °°½À´Ï´Ù. "¾î¼´Ù ¿ì¿¬È÷ ¹º°¡ ¹ß°ßµÇ¾î ´ÙÇེ·´°Ô Àß Ä¡·áµÈ °Í °°½À´Ï´Ù. Á¤¸» ¿îÀÌ ÁÁÀº °æ¿ì¶ó°í »ý°¢ÇÕ´Ï´Ù. ±×·¯³ª ȯÀÚ ºÐÀÌ ¿îÀÌ ÁÁ¾Ò´Ù°í ´Ù¸¥ ºÐµéµµ ´Ù ¿îÀÌ ÁÁÀº °ÍÀº ¾Æ´Õ´Ï´Ù. ³Ê¹« À̸¥ ³ªÀÌ¿¡ °Ë»ç¸¦ ¹Þ´Ù ºÎÀÛ¿ëÀ¸·Î °í»ýÇÏ´Â »ç¶÷µµ ¾ó¸¶µçÁö Àֱ⠶§¹®ÀÔ´Ï´Ù. À̹ø ÀÏÀº Âü ¿îÀÌ ÁÁ¾Ò´Ù°í È¥ÀÚ »ý°¢ÇÏ°í ³Ñ¾î°¡½Ã±â ¹Ù¶ø´Ï´Ù. ³²µé¿¡°Ô±îÁö ±ÇÇÒ ÀÏÀº ¾Æ´Ï°í, ´Ù¸¥ °Ë»ç¸¦ Ãß°¡·Î ¹Þ¾Æº¼ Àϵµ ¾Æ´Õ´Ï´Ù."

¹Ì±¹ ½Å¹®¿¡ ½Ç·È´ø ¿À·¡µÈ ±Û Çϳª¸¦ ¼Ò°³ÇÕ´Ï´Ù. »ó´çÈ÷ ³Ã¼ÒÀûÀÔ´Ï´Ù. ±×·¯³ª Àо¸¸ÇÕ´Ï´Ù.

If You Feel O.K., Maybe You Are O.K.

EARLY diagnosis has become one of the most fundamental precepts of modern medicine. It goes something like this: The best way to keep people healthy is to find out if they have (pick one) heart disease, autism, glaucoma, diabetes, vascular problems, osteoporosis or, of course, cancer - early. And the way to find these conditions early is through screening.

It is a precept that resonates with the intuition of the general public: obviously it¡¯s better to catch and deal with problems as soon as possible. A study published with much fanfare in The New England Journal of Medicine last week contained what researchers called the best evidence yet that colonoscopies reduce deaths from colon cancer.

Recently, however, there have been rumblings within the medical profession that suggest that the enthusiasm for early diagnosis may be waning. Most prominent are recommendations against prostate cancer screening for healthy men and for reducing the frequency of breast and cervical cancer screening. Some experts even cautioned against the recent colonoscopy results, pointing out that the study participants were probably much healthier than the general population, which would make them less likely to die of colon cancer. In addition there is a concern about too much detection and treatment of early diabetes, a growing appreciation that autism has been too broadly defined and skepticism toward new guidelines for universal cholesterol screening of children.

The basic strategy behind early diagnosis is to encourage the well to get examined - to determine if they are not, in fact, sick. But is looking hard for things to be wrong a good way to promote health? The truth is, the fastest way to get heart disease, autism, glaucoma, diabetes, vascular problems, osteoporosis or cancer ... is to be screened for it. In other words, the problem is overdiagnosis and overtreatment.

Screening the apparently healthy potentially saves a few lives (although the National Cancer Institute couldn¡¯t find any evidence for this in its recent large studies of prostate and ovarian cancer screening). But it definitely drags many others into the system needlessly - into needless appointments, needless tests, needless drugs and needless operations (not to mention all the accompanying needless insurance forms).

This process doesn¡¯t promote health; it promotes disease. People suffer from more anxiety about their health, from drug side effects, from complications of surgery. A few die. And remember: these people felt fine when they entered the health care system.

It wasn¡¯t always like this. In the past, doctors made diagnoses and initiated therapy only in patients who were experiencing problems. Of course, we still do that today. But increasingly we also operate under the early diagnosis precept: seeking diagnosis and initiating therapy in people who are not experiencing problems. That¡¯s a huge change in approach, from one that focused on the sick to one that focuses on the well.

Think about it this way: in the past, you went to the doctor because you had a problem and you wanted to learn what to do about it. Now you go to the doctor because you want to stay well and you learn instead that you have a problem.

How did we get here? Or perhaps, more to the point: Who is to blame? One answer is the health care industry: By turning people into patients, screening makes a lot of money for pharmaceutical companies, hospitals and doctors. The chief medical officer of the American Cancer Society once pointed out that his hospital could make around $5,000 from each free prostate cancer screening, thanks to the ensuing biopsies, treatments and follow-up care.

A more glib response to the question of blame is: Richard Nixon. It was Nixon who said, ¡°we need to work out a system that includes a greater emphasis on preventive care.¡± Preventive care was central to his administration¡¯s promotion of health maintenance organizations and the war on cancer. But because the promotion of genuine health - largely dependent upon a healthy diet, exercise and not smoking - did not fit well in the biomedical culture, preventive care was transformed into a high-tech search for early disease.

Some doctors have long recognized that the approach is a distraction for the medical community. It¡¯s easier to transform people into new patients than it is to treat the truly sick. It¡¯s easier to develop new ways of testing than it is to develop better treatments. And it¡¯s a lot easier to measure how many healthy people get tested than it is to determine how well doctors manage the chronically ill.

But the precept of early diagnosis was too intuitive, too appealing, too hard to challenge and too easy to support. The rumblings show that that¡¯s beginning to change.

Let me be clear: early diagnosis is not always wrong. Doctors would rather see patients early in the course of their heart attack than wait until they develop low blood pressure and an irregular heartbeat. And we¡¯d rather see women with small breast lumps than wait until they develop large breast masses. The question is how often and how far we should get ahead of symptoms.

For years now, people have been encouraged to look to medical care as the way to make them healthy. But that¡¯s your job - you can¡¯t contract that out. Doctors might be able to help, but so might an author of a good cookbook, a personal trainer, a cleric or a good friend. We would all be better off if the medical system got a little closer to its original mission of helping sick patients, and let the healthy be.


[2017-8-4. ¹Ì±¹¿¡ °è½Å ÇÑ ¼±»ý´ÔÀÇ Áú¹®]

¹Ì±¹¿¡¼­´Â À§¾ÏÀÌ Èñ±Í¾ÏÀ̶ó screening EGD¶ó´Â °³³äÀÌ ¾ø¾î, ¿©±â »ç´Â ¸¹Àº Korean Americans°¡ ¸»±â À§¾ÏÀ¸·Î ¾ï¿ïÇÏ°Ô »ç¸ÁÇϴµ¥, ÀÌ°ÍÀ» ¸·±â À§ÇÏ¿© »çȸ °è¸ùÈ°µ¿À» ÇÏ°í ÀÖÀ¾´Ï´Ù. ¸î °¡Áö ±Ã±ÝÇÑ Á¡ÀÌ Àִµ¥, ¾Æ´Â ´ë·Î ¾Ë·Á ÁÖ¸é °í¸¿°Ú¾î¿ä.

1) Çѱ¹ »ç¶÷ÀÌ "±¹¹Î °Ç°­ º¸Çè"¿¡ µé¾î ÀÖ¾î ¸ðµÎ À§³»½Ã°æÀ» °Ý³â¿¡ ¹Þ´Â´Ù°í Çϴµ¥ (¹«·á·Î), ±×·¡µµ ¸ø ¹Þ´Â »ç¶÷ÀÌ ÀÖÀ¾´Ï±î?

2) "±¹¹Î °Ç°­ º¸Çè"¿¡ ¾È µé¾î Àְųª ¸ø µé¾î ÀÖ¾î À§³»½Ã°æÀ» ¸ø ¹Þ´Â »ç¶÷ÀÌ ÀÖÁö ¾ÊÀ»±î¿ä?

3) À§ ³»½Ã°æÀ» ÇÒ¶§ ¸¶Ã븦 ¾È ÇÏ°í ÇÏ¸é ¸Å¿ì ºÒÆíÇÒ¼ö Àִµ¥, ¸¶Ã븦 ÇÏ´Â "¼ö¸é À§³»½Ã°æ"À» ÇÏ¸é ±× ºñ¿ëÀº ³»¾ßÁö¿ä? ¾ó¸¶ Á¤µµÀÎÁö ¾Æ½Ê´Ï±î?

4) ´ëºÎºÐ »ç¶÷µéÀÌ ¸¶Ã븦 ÇÕ´Ï±î ¾ÈÇմϱî?

5) °Ý³â¿¡ Çѹø¾¿ ¿À´Â "À§³»½Ã°æ ÇÏ·¯ ¿À¶ó"ÇÏ´Â ÆíÁö¸¦ ¹«½ÃÇÏ°í ¾È ÇÏ¸é ¶Ç µ¶ÃËÀåÀÌ ¿Â´Ù´øÁö, ¹«½¼ ¼º°¡½Å ÀÏÀÌ ÀÖÀ¾´Ï±î? ±×·¡¼­ ÇÒ¼ö ¾øÀÌ ¶°¹Ð·Á¼­ °£´ÙµçÁö?

6) ±¹¹Îº¸Çè¿¡ µå´Âµ¥, º¸Åë Áß»êÃþÀÌ 1³â¿¡ ¾ó¸¶¾¿ ³»¾ß Çմϱî. ¾ÆÁÖ ºó°øÃþÀÎ °æ¿ì¿¡ º¸Çè·á¸¦ ¸éÁ¦ ¹ÞÀ» ¼ö ÀÖÀ¾´Ï±î?

[2017-8-4. ÀÌÁØÇà ´äº¯]

¾È³çÇϽʴϱî. Àúµµ ±¸Ã¼ÀûÀÎ ½Ç¹«³ª µ· ¹®Á¦¿¡ ´ëÇؼ­´Â ¸ð¸£´Â ºÎºÐÀÌ ¸¹½À´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼­ À§¾Ï °ËÁø ³»½Ã°æ¿¡ ´ëÇÑ °³°³ÀÎÀÇ ºñ¿ë ºÎ´ãÀº ³Ê¹«³ª Àû½À´Ï´Ù. ÀÏ»óÀûÀÎ Áø·á¿¡¼­ µ·¹®Á¦´Â °ÅÀÇ °í·ÁÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù.

1) °ËÁøÀº ¾Æ¹«¸® °¡°ÝÀÌ ½Î´õ¶óµµ compliance°¡ 100%´Â µÇÁö ¾Ê´Â °Í °°½À´Ï´Ù. ÇöÀç ¿ì¸®³ª¶ó¿¡¼­ À§¾Ï °ËÁø compliance´Â 70% ¼±À¸·Î ¾Ë°í ÀÖ½À´Ï´Ù. ¹®Á¦´Â ¾ÆÁ÷µµ barium study·Î °Ë»ç¹Þ´Â »ç¶÷ÀÌ ÀûÁö ¾Ê´Ù´Â °ÍÀε¥, Àü¹®°¡µéÀº ±¹°¡ ¾Ï°ËÁø ÇÁ·Î±×·¥¿¡¼­ barium study¸¦ »èÁ¦ÇØ ´Þ¶ó°í Á¤ºÎ¿¡ ¿äûÇÏ°í ÀÖ´Â »óÅÂÀÔ´Ï´Ù.

2) ±¹¹Î°Ç°­º¸ÇèÀº Àü±¹¹ÎÀ» Ä¿¹öÇÏ°í ÀÖ½À´Ï´Ù. ÀϽÃÀûÀ¸·Î º¸Çè ±Þ¿© ´ë»ó¿¡¼­ ºüÁ³´õ¶óµµ Á¶±Ý¸¸ µ·À» ³»¸é ±Ý¹æ º¸Çè Àû¿ëÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. °ËÁø non-complianceÀÇ ¿øÀÎÀº ¾Æ´Õ´Ï´Ù.

3) Procedural sedation¿¡ ´ëÇÑ È¯ÀÚ ºÎ´ãÀº 5-15¸¸¿ø Á¤µµÀÔ´Ï´Ù. ÃÖ±Ù ÀϺΠ³»½Ã°æ °Ë»ç¿¡ ´ëÇÏ¿© º¸Çè±Þ¿©°¡ ½ÃÀ۵Ǿú±â ¶§¹®¿¡ ȯÀںδãÀÌ ¸Å¿ì ÀûÀº °æ¿ìµµ ÀÖ½À´Ï´Ù.

4) ÀúÈñ ±â°ü¿¡¼­ »óºÎÀ§³»½Ã°æÀÇ procedural sedationÀº 60-70% Á¤µµ¿¡¼­ ÀÌ·ç¾îÁý´Ï´Ù. Áø´Ü³»½Ã°æÀÇ °æ¿ì 100% midazolamÀ» »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù. Ÿ ÀÇ·á±â°ü¿¡¼­´Â propofolÀ» »ç¿ëÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.

5) °ËÁø ÂÊÁö¸¦ ¹«½ÃÇÑ´Ù°í ¹«½¼ ÀÏÀÌ ¹ú¾îÁöÁö´Â ¾Ê½À´Ï´Ù. ´Ù¸¸ Á¤ºÎ¿¡¼­ ±ÇÇÏ´Â °ËÁøÀ» ¹ÞÁö ¾ÊÀ¸¸é Á¦µµ»óÀÇ ºÒÀÌÀÍÀÌ ÀÖ´Ù°í Àß ¸ø ¾Ë°í °è½Ã´Â ±¹¹ÎµéÀÌ ÀÖ½À´Ï´Ù. °ø¹«¿øµéÀÌ °ËÁø ½ÇÀûÀ» ¿Ã¸®±â À§ÇÏ¿© ¾à°£ ¾Ö¸ÅÇÏ°Ô ¸»ÇÏ´Â °æ¿ì°¡ Àִµ¥, ÀÌ°ÍÀ» ±¹¹ÎµéÀÌ °ËÁøÀ» ²À ¹Þ¾Æ¾ß ÇÏ´Â °ÍÀ¸·Î ¿ÀÇØÇÏ´Â °Í °°½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ÀûÁö ¾ÊÀº È¥¼±ÀÌ ÀÖ½À´Ï´Ù. À§¾Ï Ä¡·á ÈÄ Á¤±âÀûÀ¸·Î follow upÀ» ¹Þ´Â »ç¶÷ÀÌ, °©ÀÚ±â Á¤ºÎ¿¡¼­ ³¯¶ó¿Â ÂÊÁö¸¦ º¸°í ¸çÄ¥ »çÀÌ¿¡ ´Ù½Ã ³»½Ã°æ °Ë»ç¸¦ ¹Þ´Â °æ¿ì±îÁö ÀÖ½À´Ï´Ù. ÃÖ±Ù ³»½Ã°æ °Ë»ç¸¦ ¹ÞÀº »ç¶÷¿¡°Ô ´Ù½Ã ³»½Ã°æ °Ë»ç¸¦ ¹ÞÀ¸¶ó°í ÂÊÁö¸¦ º¸³½´Ù´Â °ÍÀº ÇѽÉÇÑ ÀÏÀÔ´Ï´Ù. Àü±¹¹Î °Ç°­ Á¤º¸°¡ Á¤ºÎÀÇ ¼Õ¿¡ Àֱ⠶§¹®¿¡ ¾ó¸¶µçÁö ÇÇÇÒ ¼ö ÀÖ´Â ÀÏÀÏ °ÍÀε¥.... ¾ÈÇÏ´Â °ÍÀÎÁö, ¸øÇÏ´Â °ÍÀÎÁö, Çϱ⠽ÈÀº °ÍÀÎÁö ¾Ë ¼ö ¾ø½À´Ï´Ù. ¿©ÇÏÆ° »ç¾÷ÀÇ ±Ô¸ð¿¡ ºñÇÏ¿© Á¤±³ÇÔÀº ¶³¾îÁý´Ï´Ù.

6) '±¹¹Î°Ç°­º¸Çè'ÀÇ º¸Çè·á´Â ¹Ì±¹ÀÇ health insurance¿Í´Â ¸Å¿ì ´Ù¸¨´Ï´Ù. ¿¹ÃøµÇ´Â °Ç°­ ºñ¿ë¿¡ ´ëÇÑ º¸Çè±Ý Àû¸³ÀÇ °³³äÀÌ ¼Òµæ¿¡ ´ëÇÑ ´©Áø¼¼ °³³äÀ¸·Î °ÅµÖÁö°í ÀÖ½À´Ï´Ù. µ¶ÀçÁ¤±Ç ½ÃÀý¿¡ À߸ø ¸¸µé¾îÁø Á¦µµ°¡ ¾ÆÁ÷µµ ±×³É Áö¼ÓµÇ°í ÀÖ½À´Ï´Ù.

7) Áú¹®¿¡´Â ¾ø´Â ³»¿ëÀÌÁö¸¸ Á¦ ÀÇ°ßÀ» ÇÑ °¡Áö ºÙÀÔ´Ï´Ù. ScreeningÀ» ¹Þ´Â´Ù°í ¾ÏÀÌ ¿¹¹æµÇÁö ¾Ê½À´Ï´Ù. ¾Ï ¿¹¹æÀ» À§ÇÑ ³ë·ÂÀÌ ÇÔ²² µÇ¾î¾ß ÇÕ´Ï´Ù. Helicobacter pylori Á¦±ÕÄ¡·á¸¦ È®´ëÇÏÁö ¾Ê°í ³»½Ã°æ¸¸ ¸¹ÀÌ ÇÑ´Ù°í µÇ´Â ÀÏÀº ¾Æ´Ò °Í °°½À´Ï´Ù. Screening°ú Helicobacter Á¦±ÕÄ¡·á¸¦ ÇÔ²² ÇÏ´Â °ÍÀÌ À§¾ÏÀ¸·ÎºÎÅÍ ±¹¹ÎÀ» º¸È£ÇÏ´Â ÀÏ ¾Æ´Ñ°¡ »ý°¢ÇÕ´Ï´Ù.

[2017-8-5. ¹Ì±¹ ¼±»ý´ÔÀÇ follow-up Áú¹®]

»ó¼¼ÇÏ°Ô ¾ËÀ¸ÄÑ ÁÖ¾î ¸¹Àº µµ¿òÀÌ µÇ°Ú½À´Ï´Ù. ´ë´ÜÈ÷ °¨»çÇÕ´Ï´Ù.

Áö±Ý Helicopter·Î ÀÎÇÑ À§¾Ï ¹ß»ý·üÀÌ Àüü À§¾ÏÀÇ ¸î%³ª µÇ´ÂÁö¿¡ °üÇÑ Åë°è°á°ú°¡ ³ª¿Í ÀÖÀ¾´Ï±î? ¶Ç Helicopter°¡ Àִ ȯÀÚ¿¡°Ô¼­, ÀÌ ±ÕÀ» antibiotics·Î Á¦°ÅÇؼ­ À§¾Ï ¹ß»ý·üÀ» ³·Ãߴµ¥ ¾ó¸¶³ª È¿·üÀûÀԴϱî?

¹Ì±¹¿¡¼­µµ breath test¸¦ Çϴµ¥, ÀÌ test°¡ reliableÇմϱî? ȤÀº ´õ ¼±È£µÇ´Â test°¡ ÀÖÀ¾´Ï±î?

[2017-8-5. ÀÌÁØÇà Ãß°¡ ´äº¯]

À§¾ÏÀÇ ¸î %°¡ Ç︮ÄÚ¹ÚÅÍ ¶§¹®ÀÎÁö´Â È®Á¤ÇϱⰡ ¾î·Æ½À´Ï´Ù. °ú°ÅºÎÅÍ ÃÖ¼ÒÇÑ Àý¹ÝÀ̶ó°í ÇßÁö¸¸ »ç½ÇÀº Àý¹Ýº¸´Ù´Â ÈξÀ ¸¹´Ù°í »ý°¢ÇÕ´Ï´Ù. »ó¼¼È÷ °Ë»çÇغ¸¸é À§¾Ï ȯÀÚÀÇ 90% ÀÌ»óÀÌ Helicobacter °¨¿°ÀÌ ÀÖ½À´Ï´Ù (current ¹× past Æ÷ÇÔ).

ÇöÀç ¿ì¸®³ª¶ó¿¡¼­ À§¾Ï ¿¹¹æÀ» À§ÇÑ Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÀº ºÒ¹ýÀÔ´Ï´Ù. ¸»ÀÌ µÇÁö ¾Ê´Â´Ù°í »ý°¢ÇÏÁö¸¸ ±ÔÁ¤ÀÌ ±×·¸½À´Ï´Ù. ÇÏ·ç »¡¸® Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·áÀÇ ÀûÀÀÁõÀÌ È®´ëµÇ¾î¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù.

¾Æ·¡ PPT file¿Í YouTube µ¿¿µ»óÀ» Âü°íÇϽñ⠹ٶø´Ï´Ù. Àú´Â Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·áÀÇ È®´ë¸¦ °­·ÂÈ÷ ÁÖÀåÇÏ´Â ÀÔÀåÀÓÀ» °¨¾ÈÇÏ°í ºÁ ÁÖ½Ã¸é °¨»çÇÏ°Ú½À´Ï´Ù. Àúº¸´Ù ´Ù¼Ò À¯º¸ÀûÀÎ Àü¹®°¡µéµµ ¸¹±â ¶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î À§Ã༺ À§¿°¿¡¼­´Â Á¦±ÕÄ¡·á¸¦ ÇÏ°í ±×·¸Áö ¾ÊÀ¸¸é ÇÏÁö ¸»ÀÚ´Â µî ¿©·¯ ÀÇ°ßÀÌ ÀÖ½À´Ï´Ù. Àú´Â ´Ù Ä¡·áÇÏÀÚ´Â ÂÊÀÔ´Ï´Ù.

PPT PDF 2.8M

2017-4-4. MVP symposium

¾Æ·¡´Â 2015³â JDDW¿¡¼­ ÀϺ»ÀÇ ¾Æ»çÄ« ¼±»ý´ÔÀÌ º¸¿©ÁֽŠ½½¶óÀ̵åÀÔ´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á µî ÀûÀýÇÑ Á¤Ã¥À¸·Î À§¾Ï »ç¸ÁÀÚ¸¦ ÇöÀçÀÇ 5¸¸¸í¿¡¼­ Àý¹Ý ÀÌÇÏ·Î ÁÙÀÏ ¼ö ÀÖ´Ù´Â ÁÖÀåÀ̾ú½À´Ï´Ù.

Urea breath test´Â Ç︮ÄÚ¹ÚÅÍ Çö°¨¿°À» Æò°¡ÇÏ´Â non-invasive test Áß °¡Àå sensitivity¿Í specificity°¡ ¿ì¼öÇÕ´Ï´Ù. ¿©·¯ ȸ»ç Á¦Ç°ÀÌ ÀÖÀ¸³ª Ưº°È÷ ¼±È£µÇ´Â °ÍÀº ¾ø½À´Ï´Ù.

* Âü°í: EndoTODAY Ç︮ÄÚ¹ÚÅÍ¿Í À§¾Ï

[2017-8-10. ¹Ì±¹ ¼±»ý´ÔÀÇ follow-up Áú¹®]

Dr. Lee. Presentation Âü Àß Çϼ̽À´Ï´Ù. Dataµµ Àß º¸¾Ò½À´Ï´Ù. ±×·±µ¥, H. pylori¸¦ eradicationÇÑ ÀϺ»ÀÇ ¿¬±¸¸¦ º¸´Ï, À§¾Ï ¹ß»ý·üÀÌ ÇÑ 50% °¨¼ÒÇϴ±º¿ä. ¸¸ÀÏ ÀÌ »ç¶÷µéÀ» H. pylori eradication¸¸ ÇÏ°í screening endoscopy¸¦ ¾È Çϸé stomach cancer incidence°¡ 50% °¨¼ÒÇÏ°ÚÁö¸¸, ³ª¸ÓÁö 50%´Â advanced incurarable stage¿¡ ÀÇ»ç/º´¿ø¿¡ ¿À°Ô µÇÁö ¾ÊÀ»±î¿ä? ¹Ý¸é H. pylori eradicationÀ» ÇÏÁö ¾Ê°í annual screening EGD¸¸ Çϸé, ±×·¡µµ advanced incurarable stage¿¡ ¿Ã ¼ö ÀÖ°ÚÁö¸¸, ±× °¡´É¼ºÀÌ ¾ó¸¶³ª µË´Ï±î?

[2017-8-19. ÀÌÁØÇà ´äº¯]

ĪÂùÀÇ ¸»¾¸ °¨»çÇÕ´Ï´Ù. Àú´Â ÀûÀýÇÑ ½ÃÁ¡ÀÇ Á¦±ÕÄ¡·á·Î ÃÖ¼ÒÇÑ À§¾ÏÀ» Àý¹ÝÀ¸·Î ÁÙÀÏ ¼ö ÀÖ´Ù°í ¹Ï´Â ÆíÀÔ´Ï´Ù. ´ëºÎºÐÀÇ ÀÚ·á°¡ ±×·¯ÇÑ ¹æÇâÀ» ÁöÁöÇÏ°í ÀÖ½À´Ï´Ù.

H. pylori Á¦±ÕÄ¡·á¸¦ ÇÏÁö ¾Ê°í ¸Å³â °ËÁø³»½Ã°æ¸¸ ÇÑ °æ¿ì advanced incurarable stageÀÇ °¡´É¼ºÀÌ ¾ó¸¶ÀÎÁö ¹®ÀÇÇϽŠºÎºÐ¿¡ ´ëÇÏ¿© Á¤È®È÷ ´äº¯µå¸®±â´Â ¾î·Æ½À´Ï´Ù. ±×·¯³ª ¾Æ·¡ÀÇ Á¤º¸¿¡¼­ ´ë°­ÀÇ Ãß·ÐÀº °¡´ÉÇÕ´Ï´Ù.

(1) °ËÁø ³»½Ã°æ¿¡¼­ À§¾ÏÀº 0.2-0.5%¿¡¼­ ¹ß°ßµË´Ï´Ù. °ËÁø ³»½Ã°æ ¹ß°ß ¹ß°ß À§¾Ï Áß 3/4´Â Á¶±âÀ§¾Ï, 1/4´Â ÁøÇ༺À§¾ÏÀÔ´Ï´Ù (Lee JH. J Gastroenterol Hepatol 2008). ´Ü, °ËÁø ¹ß°ß À§¾ÏÀ» ¸ðµÎ '¹«Áõ»ó À§¾Ï'À¸·Î º¼ ¼ö´Â ¾ø½À´Ï´Ù. À§Àå°ü Áõ»óÀ¸·Î ÀÎÇÏ¿© '°ËÁøÀ» ¹Þ¾Æº¸ÀÚ'°í »ý°¢ÇÏ´Â »ç¶÷ÀÌ ¸¹±â ¶§¹®ÀÔ´Ï´Ù. ±¹°¡¿¡¼­ Á¦°øÇÏ´Â ¾Ï°ËÁø ÇÁ·Î±×·¥À¸·Î °Ë»ç¸¦ ¹Þ´Â °ÍÀÌ ÀÏ»óÀûÀÎ ¿Ü·¡Áø·áº¸´Ù ºü¸£°í ½Î±â ¶§¹®ÀÔ´Ï´Ù. ´ëÇüº´¿ø¿¡¼­ Á¦°øÇÏ´Â »çÀûÀÎ 'Á¾ÇÕ °ÇÁø'Àº ´Ù¼Ò ºñ½ÎÁö¸¸ ÀüÈ­·Î ¿¹¾àÇÑ ÈÄ ÂªÀº ½Ã°£¿¡ ¸¹Àº °Ë»ç¸¦ ¹ÞÀ» ¼ö ÀÖ´Ù´Â Á¡ ¶§¹®¿¡ º¹ÅëÀÌ »ý°åÀ» ¶§ ³»°ú ¿Ü·¡¸¦ ãÁö ¾Ê°í °ÇÁø ¼¾ÅÍ¿¡ ÀüÈ­Çϴ ȯÀÚµµ ÀÖ½À´Ï´Ù. »ó½ÄÀûÀ¸·Î ¸»µµ ¾È µÇ´Â ÀÏÀÌÁö¸¸ ¿ì¸® ³ª¶ó¿¡¼­´Â ´Ù¹Ý»ç·Î ÀϾ´Â ÀÏÀÔ´Ï´Ù. ÇѽÉÇÏ´Ù°í »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù.

(2) °ËÁø ³»½Ã°æ ¹ß°ß Á¶±âÀ§¾ÏÀÇ 60% Á¤µµ´Â differentiated type histology (W/D, M/D)ÀÌ°í ³ª¸ÓÁö 40% Á¤µµ´Â undifferentiated type histology (P/D, SRC)ÀÔ´Ï´Ù. ¾Æ»êº´¿ø °ËÁø¼¾ÅÍ ÀڷḦ ºÐ¼®ÇÑ ¾Æ·¡ tableÀ» Âü°íÇϽñ⠹ٶø´Ï´Ù (Lee JY. Gut Liver 2017 - Epub). ¾Æ»êº´¿ø¿¡¼­´Â Lauren ¹æ¹ýÀ¸·Î ºÐ·ùÇÏ¿´À» ¶§ intestinal typeÀÌ 61.7%, diffuse typeÀÌ 38.3%¿´½À´Ï´Ù.

Gut Liver 2017

(3) °ËÁø ³»½Ã°æ ¹ß°ß À§¾ÏÀº ´ëºÎºÐ Helicobacter °¨¿°°ú °ü·ÃµÇ¾î ÀÖ½À´Ï´Ù. ¾Æ»êº´¿ø °ËÁø¼¾ÅÍ ÀÚ·á¿¡¼­ H. pylory Ç×ü ¾ç¼º·üÀÌ intestinal type¿¡¼­´Â 75.9%, diffuse type¿¡¼­´Â 90.7%¿´À¸¸ç, Ç×ü ¿ª°¡°¡ ³ôÀ»¼ö·Ï diffuse typeÀÇ ºñÀ²ÀÌ ³ô¾ÆÁ³½À´Ï´Ù.

Gut Liver 2017

¸Õ °ú°Å¿¡´Â H. pylori °¨¿°ÀÌ ÁÖ·Î intestinal type¿¡¸¸ °ü¿©ÇÏ°í ÀÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁ³Áö¸¸, ±Ù°£¿¡´Â H. pylori °¨¿°ÀÌ intestinal type°ú diffuse type ¸ðµÎ¿¡ °ü¿©ÇÑ´Ù´Â °ÍÀÌ »ó½ÄÀÌ µÇ¾ú½À´Ï´Ù. ¾Æ»êº´¿ø °ËÁø¼¾ÅÍ ³í¹®¿¡¼­ ÀúÀÚµéÀº intestinal typeÀÇ H. pylori Ç×ü ¾ç¼º·üÀÌ ³·Àº °ÍÀº ¾Æ¸¶µµ À§Ã༺ º¯È­°¡ ½ÉÇÏ¿© H. pylori°¡ ÀÚ¿¬ ¼Ò½ÇµÇ¾ú±â ¶§¹®ÀÎ °ÍÀ¸·Î Çؼ®ÇÏ°í ÀÖ½À´Ï´Ù. µ¿ÀÇÇÕ´Ï´Ù. H. pylori°¡ °ü¿©ÇÏÁö ¾Ê´Â À§¾ÏÀÌ ÀÖ±â´Â ÇÏÁö¸¸ ÈçÇÑ ÀÏÀº ¾Æ´Õ´Ï´Ù. ¸Å¿ì µå¹® ÀÏ·Î »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù.

Gut Liver 2017

H. pylori À½¼º À§¾ÏÀº ¿ö³« µå¹® ÀÏÀ̹ǷΠspecial lectureÀÇ ÁÖÁ¦°¡ µÇ°ï ÇÕ´Ï´Ù. 2017³â ÇÑÀÏ Helicobacter ÇÐȸ¿¡¼­ ÀϺ» Sugano ¼±»ý´ÔÀÌ H. pylori À½¼º À§¾Ï¿¡ ´ëÇÏ¿© »ó¼¼ÇÑ °­ÀǸ¦ ÇØ Áּ̽À´Ï´Ù. 2017³â 8¿ù 27ÀÏ ¿­¸± ³»½Ã°æÇÐȸ ¼¼¹Ì³ª¿¡¼­µµ °Ç¾ç´ëÇб³ ¼Û°æÈ£ ¼±»ý´ÔÀÌ ÀÌ ÁÖÁ¦¿¡ ´ëÇÑ °­ÀǸ¦ ÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¾Æ·¡ ¸µÅ©¸¦ Âü°íÇϽñ⠹ٶø´Ï´Ù.

* Âü°í: 2017³â 4¿ù 8ÀÏ Dr. Sugono Ư°­ - Helicobacter À½¼º À§¾Ï

* Âü°í: 2017³â 8¿ù 27ÀÏ ³»½Ã°æÇÐȸ ¼¼¹Ì³ª ¼Û°æÈ£ ±³¼ö´Ô °­ÀÇ - Helicobacter À½¼º À§¾Ï

(4) °ËÁø ³»½Ã°æ ¹ß°ß Á¶±âÀ§¾ÏÀÇ Àý¹ÝÀº ³»½Ã°æÀýÁ¦¼ú·Î Ä¡·áÇÏ°í ÀÖ½À´Ï´Ù. ÇöÀç ¿ì¸®³ª¶ó¿¡¼­ ¹ß°ßµÇ´Â À§¾ÏÀÇ 25-30% Á¤µµ´Â ³»½Ã°æÀ¸·Î Ä¡·áµÇ°í ÀÖ½À´Ï´Ù. ¾Æ»êº´¿ø °ËÁø¼¾ÅÍ ÀڷḦ ºÐ¼®ÇÑ ¾Æ·¡ tableÀÇ ¸Ç ÇÏ´ÜÀ» Âü°íÇϽñ⠹ٶø´Ï´Ù.

Gut Liver 2017

2017³â ´ëÇÑÀ§¾ÏÇÐȸ Çмú´ëȸ¿¡¼­ À§¾Ï °ËÁø¿¡ ´ëÇÑ ½ÉÆ÷Áö¾öÀÌ ÀÖ¾ú½À´Ï´Ù. 2016³â »ï¼º¼­¿ïº´¿ø °ËÁø ½ÉÆ÷Áö¾ö¿¡µµ Èï¹Ì·Î¿î ³»¿ëÀÌ ¸¹½À´Ï´Ù. ¾Æ·¡ ¸µÅ©¸¦ Âü°íÇϽñ⠹ٶø´Ï´Ù.

* Âü°í: 2017-3-23. KINGCA À§¾Ï °ËÁø ½ÉÆ÷Áö¾ö

* Âü°í: 2016-3-27. »ï¼º¼­¿ïº´¿ø °Ç°­ÀÇÇк»ºÎ 20Áֳ⠱â³ä ½ÉÆ÷Áö¾ö

(5) Á¤ºÎ¿¡¼­ ÁøÇàÁßÀÎ ±¹°¡¾Ï°ËÁø ÇÁ·Î±×·¥ÀÇ »ýÁ¸À² Çâ»ó È¿°ú´Â ±¹¸³¾Ï¼¾ÅÍ ÃÖÀÏÁÖ ¼±»ý´Ô ÆÀ¿¡¼­ 2017³â Gastroenterology Áö¿¡ 'Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality'¶ó´Â Á¦¸ñÀ¸·Î ¹ßÇ¥ÇÏ¿´½À´Ï´Ù (Jung JK. Gastroenterology 2017).

ºÐ¸í »ç¸Á·üÀÌ Àý¹Ý ÀÌÇÏ·Î °¨¼ÒÇÏÁö¸¸ ¹Ýº¹ÀûÀÎ °Ë»ç¿¡µµ ºÒ±¸ÇÏ°í À§¾ÏÀ¸·Î »ç¸ÁÇϴ ȯÀÚµµ Á¦¹ý ÀÖ¾ú½À´Ï´Ù. À̹ø ¿¬±¸¸¦ ÅëÇÏ¿© À§³»½Ã°æÀº »ç¸Á·ü °¨¼Ò È¿°ú°¡ ÀÖ´Â ¹Ý¸é, À§ÀåÁ¶¿µ¼úÀº È¿°ú°¡ ¾ø´Ù´Â °ÍÀÌ ´Ù½Ã Çѹø È®ÀεǾú°í 75¼¼ ÀÌ»ó °í·É¿¡¼­´Â °ËÁø ³»½Ã°æÀÌ À¯¿ë¼ºÇÏÁö ¾ÊÀ½À» º¸¿©ÁÖ¾ú½À´Ï´Ù (°°Àº ÀڷḦ ±Ù°Å·Î °ËÁø ³»½Ã°æ ¿¬·É »óÇѼ±À» ¼³Á¤ÇÑ À§¾Ï °ËÁø ±Ç°í¾ÈÀÌ ´ëÇÑÀÇ»çÇùȸÁö 2015³â 5¿ùÈ£¿¡ ¹ßÇ¥µÇ¾ú´Âµ¥ ¾ÆÁ÷ ±¹°¡ Á¤Ã¥¿¡ ¹Ý¿µµÇÁö ¾Ê¾Ò½À´Ï´Ù. ÀÌ ¶ÇÇÑ ÇѽÉÇÑ ÀÏÀÔ´Ï´Ù. ¾Ö½á ¸¸µç ±Ç°í¾ÈÀÌ ÀÔ¸À¿¡ ¸ÂÁö ¾Ê¾Ò´ø ¸ð¾çÀÔ´Ï´Ù. °ËÁø ±Ç°í¾ÈÀÌ ´Ù½Ã ¸¸µé¾îÁö°í ÀÖ´Ù´Â ÈĹ®ÀÔ´Ï´Ù). À̹ø¿¡ ¹ßÇ¥µÈ ÀÚ·á´Â ¾Ï°ËÁø »ç¾÷ ÃʱâÀÇ È¯ÀÚµéÀÌ ´ë»óÀ̹ǷΠÇöÀç´Â ¼ºÀûÀÌ Çâ»óµÇ¾úÀ» °ÍÀ¸·Î »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù.

* Âü°í: EndoTODAY °ÇÁø À§³»½Ã°æÀ» ¸î ¼¼¿¡ Áß´ÜÇÒ °ÍÀΰ¡?

¿ä¾àÇÏ°Ú½À´Ï´Ù. º¸¼öÀûÀ¸·Î »ý°¢ÇÏ´õ¶óµµ (1) ÀûÀýÇÑ ¿¬·É¿¡ H. pylori¸¦ Á¦±ÕÇϸé À§¾Ï ¹ß»ý·üÀÌ Àý¹ÝÀ¸·Î °¨¼ÒµÇ°í, (2) 2³â¿¡ Çѹø À§³»½Ã°æÀ» ¹ÞÀ¸¸é À§¾ÏÀ¸·Î ÀÎÇÑ »ç¸Á·üÀÌ Àý¹Ý ÀÌÇÏ·Î ¶³¾îÁý´Ï´Ù. (1) Á¦±ÕÄ¡·á ÀûÀÀÁõÀÌ È®´ëµÇ°í, (2) °ËÁø¸ñÀûÀÇ ¹Ù·ýÁ¶¿µ¼úÀÌ »ç¶óÁö°í, (3) °ËÁø³»½Ã°æ ÁúÇâ»ó ³ë·ÂÀÌ Àß ÀÌ·ç¾îÁö¸é ±× °á°ú´Â ´õ¿í ÁÁ¾ÆÁú °ÍÀÔ´Ï´Ù (³»½Ã°æ ÁúÇâ»ó ³ë·ÂÀº Á¤¸» Áß¿äÇÕ´Ï´Ù). ±×·¯³ª ¾Æ¹«¸® Á¦±ÕÄ¡·á¸¦ ÀÏÂï ¹Þ´õ¶óµµ, ¾Æ¹«¸® ³»½Ã°æ °Ë»ç¸¦ ÀÚÁÖ ¹Þ´õ¶óµµ ÀϺΠȯÀÚ¿¡¼­´Â Ä¡·áÇÒ ¼ö ¾ø´Â À§¾ÏÀÌ ¹ß°ßµË´Ï´Ù. ºóµµ´Â ¾Ë ¼ö ¾ø½À´Ï´Ù. °³ÀÎÀûÀ¸·Î´Â 10% ¹Ì¸¸ÀÏ °ÍÀ¸·Î »ý°¢(ȤÀº Èñ¸Á)ÇÏ°í ÀÖ½À´Ï´Ù.

´Ù ÇÔ²² ³ë·ÂÇϸé 90% ÀÌ»óÀ» ¸·À» ¼ö ÀÖ´Ù...... Á¤¸» ¸ÚÁø ÀÏ ¾Æ´Õ´Ï±î? º¸¶÷°ú Èñ¸Á°ú Ã¥ÀÓ°¨À» ÇÔ²² ´À³§´Ï´Ù.

°¨»çÇÕ´Ï´Ù.

[2017-8-19. EndoTODAY ºí·Î±× µ¶ÀÚ comment]

¿£µµÅõµ¥À̸¦ ÅëÇØ ÁÁÀº °¡¸£Ä§À» Áֽô ÀÌÁØÇà±³¼ö´Ô²² Ç×»ó °¨»çµå¸®°í ÀÖ½À´Ï´Ù.

Ç︮ÄÚ¹ÚÅ͸¦ Àû±ØÀûÀ¸·Î Ä¡·áÇÏ°í À̷νá À§¾ÏÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù´Â °Í¿¡ ÀüÀûÀ¸·Î µ¿ÀÇÇÏ°í ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ÇÑÆí µå´Â »ý°¢ÀÌ ÀÖ½À´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ´Â ÀÌ¹Ì ¼öõ³â µ¿¾È ÀηùÀÇ À§¿¡¼­ »ì¾Æ ¿Ô°í Ç×»ýÁ¦ Ä¡·á·Î ÀÌ ¼¼±ÕÀ» ¿ÏÀüÈ÷ ¹Ú¸êÇÏ´Â °ÍÀº ºÒ°¡´ÉÇϸ®¶ó°í »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. ±×·¸´Ù¸é ±¤¹üÀ§ÇÑ Á¦±ÕÄ¡·á´Â ¹°·Ð À¯º´·üÀº ³·Ãâ ¼ö ÀÖ°ÚÁö¸¸ ¿ÀÈ÷·Á ³»¼º±ÕÁÖÀÇ Ã¢±ÈÀ» ºÒ·¯¿ÀÁö ¾ÊÀ»±îÇÏ´Â ¿ì·Á°¡ µì´Ï´Ù. ±×·¡¼­ ÀúÈñ³ª ÀúÈñÀÇ ÂªÀº ÈļձîÁö´Â ³·Àº À¯º´·üÀÇ ÇýÅÃÀ» º¼ ¼öµµ ÀÖ°ÚÁö¸¸ ±× ÀÌÈĸ¦ º¸¸é ¾àÁ¦ ³»¼ºÀ» °¡Áø Ç︮ÄÚ¹ÚÅͱÕÀ¸·Î ÀÎÇØ Àηù°¡ ´õ Å« ¾î·Á¿òÀ» °Þ°Ô µÇÁö ¾ÊÀ»±îÇÏ´Â »ý°¢µµ µì´Ï´Ù. ÇöÀçÀÇ VRE³ª CRE µîÀÌ ¹®Á¦°¡ µÇ°í â±ÈÀÇ °¡´É¼ºµµ ÀÖ´Â °ÍÀÌ ¿¹°¡ ¾Æ´Ò±î ½Í½À´Ï´Ù.

¶ÇÇÑ Ç︮ÄÚ¹ÚÅÍ°¡ ¾ø´Â À§¿¡¼­´Â GERD³ª Barrett ½Äµµ, ÀÚ°¡¸é¿ª ÁúÈ° µîÀÇ À¯º´·üÀÌ Áõ°¡ÇÒ ¼öµµ ÀÖ´Ù°í µÇ¾î ÀÖ¾î Çϳª¸¦ ¾òÁö¸¸ ¶Ç ´Ù¸¥ Çϳª¸¦ ÀÒÀ» ¼öµµ ÀÖÁö¾ÊÀ»±î ÇÕ´Ï´Ù. ÀÌÀü¿¡ ÀϺ»¿¡¼­ Barrett ½Äµµ°¡ Áõ°¡ÇÏ°í ÀÖ´Ù´Â ½½¶óÀ̵带 ¿Ã·Á ÁÖ¼ÌÀ» ¶§ ÀϺ»ÀÇ °ø°ÝÀûÀÎ Ç︮ÄÚ¹ÚÅÍ Ä¡·á¿Í °ü·ÃÀÌ ÀÖÁö ¾ÊÀ»±î »ý°¢µµ Çغ¸¾Ò½À´Ï´Ù.

Àεµ³ª ÆÄÅ°½ºÅº µîÀÇ Áß¾Æ½Ã¾Æ Áö¹æ °°Àº °æ¿ì Ç︮ÄÚ¹ÚÅÍ ¼¼±ÕÀÇ °¨¿°·üÀÌ ³ôÀ½¿¡µµ À§¾ÏÀÇ À¯º´·üÀº ³·°í ÀÌ´Â µ¿¾Æ»çÀÌÀÇ ³ôÀº À¯º´·ü°ú ºñ±³ÇØ Asian enigma·Îµµ ºÒ¸®°í ÀÖ½À´Ï´Ù.¹°·Ð Ç︮ÄÚ¹ÚÅÍ ¼¼±ÕÀÇ virulence factor°¡ ÇÑ ÀÎÀÚ·Î ÀÌÇصǰí ÀÖÁö¸¸ ÀϺΠÀúÀÚ´Â ³ªÆ®·ýÀÌ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ̶ó°í À̾߱âÇÏ°í ÀÖ½À´Ï´Ù. Àü¼¼°è¿¡¼­ °¡Àå ¼öÁØÀÇ ³ôÀº ³ªÆ®·ý ¼·Ã븦 º¸ÀÌ´Â Çѱ¹¿¡¼­ À§¾ÏÀÇ À¯º´·üÀÌ Àü¼¼°èÀûÀÎ °ÍÀÌ ³ªÆ®·ýÀÇ ¿µÇâÀÏ °ÍÀ̶ó°í Àú´Â »ý°¢À» ÇÏ°í ÀÖ½À´Ï´Ù. ±×·¡¼­ Àú´Â Ç︮ÄÚ¹ÚÅÍ ¼¼±Õ Ä¡·áº¸´Ù ¿ÀÈ÷·Á ³ªÆ®·ý ¼·Ã븦 ÁÙÀÌ´Â Àü±¹¹ÎÀûÀÎ ½Ä»ýÈ° °³¼± ¿îµ¿ÀÌ ´õ Áß¿äÇÏÁö ¾ÊÀ»±î »ý°¢ÇÕ´Ï´Ù. ³ªÆ®·ý ¼·Ã븦 ÁÙÀÌ´Â °ÍÀº ½ÉÇ÷°ü ÁúÈ°À» ÁÙÀÌ´Â ºÎ°¡ÀûÀÎ ÀÌÁ¡µµ ÀÖÁö¸¸ ºÎÀÛ¿ëÀº °ÅÀÇ ¾øÀ» Å״ϱî¿ä.

º»¹®ÀÇ ÁÖÁ¦¿Í´Â ´Ù¼Ò °Å¸®°¡ ÀÖÁö¸¸ Ç︮ÄÚ¹ÚÅÍ¿Í À§¾ÏÀ̶ó´Â ÁÖÁ¦°¡ ³ª¿Í Æò¼Ò °¡Áö°í ÀÖ´ø ªÀº »ý°¢°ú Àǹ®À» ÀÌ ÀÚ¸®¸¦ ºô·Á Àû¾î º¸¾Ò½À´Ï´Ù. °¨»çÇÕ´Ï´Ù.

[2017-8-19. ÀÌÁØÇà ´äº¯]

¿©·¯ ÀÇ°ßÀÌ °¡´ÉÇÒ °Í °°½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÑ À̽´¸¦ ÇØ°áÇÏ´Â °¡Àå ÁÁÀº ¹æ¹ýÀº ±Ù°ÅÀÔ´Ï´Ù. ÁÁÀº Àӻ󿬱¸°¡ ±× ÇØ´äÀÏ °ÍÀÔ´Ï´Ù. ÃÖ¼±ÀÇ Àӻ󿬱¸°¡ ¾ø´Ù¸é Â÷¼±ÀÇ Àӻ󿬱¸¿Í ÀûÀýÇÑ ÃßÁ¤¿¡ µû¸¥ ÆÇ´ÜÀÌ ÇÊ¿äÇÏ°ÚÁö¿ä. Ç︮ÄÚ¹ÚÅÍ¿¡ ´ëÇؼ­´Â ÃÖ¼±ÀÇ Àӻ󿬱¸´Â ¾øÀ¸³ª Â÷¼±ÀÇ ÀÚ·á´Â ¸¹ÀÌ ÃàÀûµÇ¾î ÀÖ½À´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á¸¦ ¹Ýµå½Ã ÇØ¾ß ÇÏ´Â Àý´ë ÀûÀÀÁõÀ¸·Î ³ÖÁö´Â ¸øÇÏ´õ¶óµµ ÃÖ¼ÒÇÑ ¿øÇÏ´Â »ç¶÷Àº ¾ðÁ¦µçÁö Ä¡·á¹ÞÀ» ¼ö ÀÖ´Â Á¤µµ±îÁö´Â Çã¿ëÇØ ÁÖ¾î¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù. Áö±Ýó·³ ºÒ¹ý Áø·áÀÇ ¿µ¿ªÀ¸·Î ³²±â´Â °ÍÀº ¹Ù¶÷Á÷ÇÏÁö ¾Ê½À´Ï´Ù. Helicobacter enigma³ª Á¦±ÕÄ¡·áÀÇ ºÎÀÛ¿ë, Ç×»ýÁ¦ ÀúÇ×¼º ¿ì·Á µîÀ» ¸ðµÎ °í·ÁÇÏ´õ¶óµµ ¸¹Àº °æ¿ì Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á ÀÚü¸¦ ºÒ¹ýÀ¸·Î °£ÁÖÇÏ´Â ¿ì¸®³ª¶óÀÇ Á¤Ã¥Àº Å« ¹®Á¦°¡ ÀÖ½À´Ï´Ù.

³ªÆ®·ý ¼·Ã븦 ÁÙÀ̸é ÁÁ°ÚÁö¸¸ Çö½ÇÀûÀ¸·Î´Â ½±Áö ¾ÊÀº °úÁ¦ÀÔ´Ï´Ù. ±× È¿°úµµ ÀÔÁõµÈ ¹Ù ¾ø½À´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ¿¡ ºñÇÏ¸é ±Ù°Å´Â °ÅÀÇ ¾ø´Ù°í º¸¾Æµµ ÁÁ½À´Ï´Ù. ÀϹÝÀûÀÎ °Ç°­°ü¸® Â÷¿ø¿¡¼­ ³ªÆ®·ý ¼·Ã븦 ÁÙÀ̵µ·Ï ±ÇÇÏ´Â Ä·ÆÐÀÎ Á¤µµ°¡ Àû´çÇÒ °Í °°½À´Ï´Ù.

[2017-8-20. ¹Ì±¹ ¼±»ý´ÔÀÇ followup Áú¹®]

Hi Dr. ÀÌ ÁØÇà,

ÁÁÀº data¸¦ ¸¹ÀÌ º¸³»Á־ °¨»çÇÕ´Ï´Ù. À§³»½Ã°æÀ» Á¤±âÀûÀ¸·Î ¹Þ¾Æµµ 1/4¿¡¼­ ÁøÇ༺ À§¾ÏÀ¸·Î ¹ß°ßµÈ´Ù°í Çϼ̴µ¥ ³» ¿¹»óº¸´Ù ¸¹Àº ¼ýÀÚÀÔ´Ï´Ù. Dr. °­µµ ºñ½ÁÇÑ statement¸¦ Çߴµ¥¿ä, È®½ÇÇÑ Åë°è´Â ¾ËÁö ¸øÇÑ´Ù Çϵ২ä. 2°¡Áö follow-up Áú¹®ÀÌ Àִµ¥¿ä;-----

1) ÀÌ ÁøÇ༺ À§¾ÏÁß¿¡µµ,stage 4´Â ¹°·Ð incurableÇÏ°ÚÁö¸¸, stage 2³ª 3ÀÏ °æ¿ì¿¡´Â radical resectionÀ» ÇÏ°í follow-up chemoradiotherapy·Î cure °¡´É¼ºÀÌ ÀÖÁö ¾ÊÀ»±î¿ä?

2) ÀϺ»¿¡ »ç´Â ³» 4ÃÌÀº 1³â¿¡ EGD¸¦ 2¹ø ¹Þ´Â´Ù´Âµ¥, ÇѹøÀº ȸ»ç¿¡¼­ ÇØÁִϱî, ¶Ç ÇѹøÀº Àڱ⠺¸Çè¿¡¼­ coverÇϴϱî. Çѱ¹¿¡µµ ÀÌ·± °æ¿ì°¡ ÀÖÀ¾´Ï±î? ÀÌ·¸°Ô 2¹ø ÇØ¾ß ¿ÇÁö ¾Ê½À´Ï±î? ±×·±µ¥ ¹Ý´ë·Î Áö±Ý Çѱ¹¿¡¼­´Â 2³â¿¡ Çѹø¾¿ ÇÏ°Ô µÇ ÀÖ±º¿ä---¿©±â¿¡ Åë°èÇÐÀû ±Ù°Å°¡ ÀÖÀ¾´Ï±î?

PS; I am taking liberty of copying this communication to Dr. Eunjung Lee, an epidemiologist at USC (Norris Comprehensive Cancer Center) as she has scholarly interest and has published recently on Korean American Cancer Disprity in one of AACR journals. She may have valuable input on this matter. Also to Dr. Çѽ½Å, the President of "¼­¿ïÀÇ´ë¹ÌÁÖµ¿Ã¢È¸", as this issue is likely to be discussed at the Annual Convention of this "¼­¿ïÀÇ´ë¹ÌÁÖµ¿Ã¢È¸".

[2017-8-20. ÀÌÁØÇà ´äº¯]

Á¦ ´äº¯ÀÌ ¾à°£ clearÇÏÁö ¾Ê¾Ò´ø °Í °°½À´Ï´Ù.

1. °ËÁø ³»½Ã°æ ¹ß°ß À§¾Ï Áß ÁøÇ༺ À§¾ÏÀÇ ºñÀ²¿¡ ´ëÇÏ¿©

"À§³»½Ã°æÀ» Á¤±âÀûÀ¸·Î ¹Þ¾Æµµ 1/4¿¡¼­ ÁøÇ༺ À§¾ÏÀ¸·Î ¹ß°ß"µÇ´Â °ÍÀº ¾Æ´Õ´Ï´Ù. °ÇÁø¼¾ÅÍ¿¡¼­ ¹ß°ßµÈ À§¾ÏÀÇ 1/4 Á¤µµ°¡ ÁøÇ༺ À§¾ÏÀ̶ó´Â ÀǹÌÀÏ »Ó, ±×µéÀÌ Á¤±âÀûÀ¸·Î °ËÁøÀ» ¹Þ´ø ºÐÀ̶ó´Â Àǹ̴ ¾Æ´Õ´Ï´Ù. °ÇÁø¼¾ÅÍ¿¡¼­ ¹ß°ßµÈ À§¾Ï ȯÀÚÀÇ »ó´ç¼ö´Â óÀ½ ³»½Ã°æÀ» ¹ÞÀº »ç¶÷µéÀÔ´Ï´Ù. ƯÈ÷ Á¤±âÀûÀÎ ³»½Ã°æ °Ë»ç¿¡ ¹«°ü½ÉÇÏ°Ô »ì´Ù°¡ ¾î´À ³¯ °©Àڱ⠺¹ÅëÀÌ ÀÖ¾î °ÇÁø¼¾Å͸¦ ã¾Æ À§¾ÏÀÌ Áø´ÜµÈ ȯÀÚµéÀÌ ¸¹ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

ÀÏÀü¿¡ ¸»¾¸µå¸° ¹Ù¿Í °°ÀÌ ¿Ü·¡Áø·áº¸´Ù °ÇÁø¼¾ÅÍ¿¡¼­ÀÇ °Ë»ç°¡ Æí¸®ÇÑ Á¡ÀÌ Àֱ⠶§¹®¿¡ ¿ì¸®³ª¶ó °ÇÁø µ¥ÀÌŸ¿¡´Â symptomatic patient°¡ ¸¹ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ±×·¡¼­ ÁøÇ༺ À§¾ÏÀÇ ºñÀ²ÀÌ ¿¹»óº¸´Ù ³ôÀº °ÍÀÔ´Ï´Ù.

2³â¸¶´Ù Á¤±âÀûÀ¸·Î ³»½Ã°æÀ» ¹Þ´Â »ç¶÷¿¡¼­ Á¶±âÀ§¾Ï°ú ÁøÇ༺À§¾ÏÀÇ ºñÀ²ÀÌ ¾ó¸¶ÀÎÁö Á¤È®ÇÑ µ¥ÀÌŸ¸¦ È®º¸Çϱâ´Â ¾î·Æ½À´Ï´Ù. (1) 2³â¸¶´Ù Á¤±âÀûÀ¸·Î ³»½Ã°æÀ» ¹Þ´Â »ç¶÷ÀÌ ¸¹Áö ¾Ê°í (¸¹Àº ȯÀÚ¿¡¼­ °Ë»ç °£°ÝÀÌ ºÒ±ÔÄ¢ÇÏ´Ù´Â ÀǹÌÀÔ´Ï´Ù), (2) ¸¹Àº ºÐµéÀÌ ÇÑ °÷¿¡¼­ °è¼Ó °Ë»ç¸¦ ¹ÞÁö ¾Ê°í ÀÌ°÷ Àú°÷À» ¿Å°Ü´Ù´Ï¸é¼­ °Ë»ç¸¦ ¹Þ°í À־ °³º° °ËÁø¼¾ÅÍ¿¡¼­´Â 'Á¤±âÀûÀ¸·Î °Ë»ç¹Þ´Â ºÐÀÇ À§¾ÏÀÇ ÁßÁõµµ' °°Àº ÀڷḦ ºÐ¼®ÇÒ ¼ö ¾ø½À´Ï´Ù. ±×·¡¼­ ±¹°¡Â÷¿øÀÇ ÀڷḦ È®º¸Çؾ߸¸ ÇØ´äÀÌ ³ª¿Ã ¼ö ÀÖ½À´Ï´Ù¸¸....

(1) Á¤ºÎ ÇÁ·Î±×·¥ÀÌ ¾Æ´Ñ »çÀû °ÇÁø¼¾ÅÍ¿¡¼­ Àڱ⠵· 100%·Î °Ë»ç¹Þ´Â »ç¶÷ÀÇ ÀÚ·á´Â Á¤ºÎ¿¡ º¸°íµÇÁö ¾Ê°í ÀÖÀ¸¸ç, (2) Á¤ºÎ¿¡ º¸°íµÇ´Â ÀÚ·á¶ó°í ÇÏ´õ¶óµµ Á¶±âÀ§¾Ï°ú ÁøÇ༺À§¾ÏÀÇ ±¸ºÐÀÌ ¸íÈ®ÇÏÁö ¾Ê½À´Ï´Ù. ±×·¡¼­ Á¤ºÎ¿¡¼­ ¹ßÇ¥ÇÑ ÃÖ¼±ÀÇ ÀÚ·áÀÎ ±¹¸³¾Ï¼¾ÅÍ ÃÖÀÏÁÖ ¼±»ý´Ô ÆÀÀÇ ³í¹® (Jung JK. Gastroenterology 2017)¿¡µµ °Ë»ç Ƚ¼ö¿Í »ýÁ¸À² °ü°è¸¸ Á¦½ÃµÇ¾úÀ» »Ó ÁøÇ༺À§¾ÏÀÇ ºñÀ²¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®ÀÌ Æ÷ÇԵǾî ÀÖÁö ¾ÊÀº °ÍÀÔ´Ï´Ù. ¿äÄÁµ¥ Á¤±âÀûÀ¸·Î À§³»½Ã°æÀ» ¹Þ´Â »ç¶÷¿¡¼­ ÁøÇ༺ À§¾ÏÀÇ ºñÀ²Àº 1/4º¸´Ù ÈξÀ ³·À» °ÍÀ¸·Î ÃßÃøµË´Ï´Ù¸¸, Á¤È®ÇÑ ÀÚ·á´Â È®º¸Çϱ⠾î·Æ½À´Ï´Ù.

2. ÀûÀýÇÑ °ËÁø ³»½Ã°æÀÇ °£°Ý¿¡ ´ëÇÏ¿©

°ËÁø À§³»½Ã°æÀÇ °£°Ý¿¡ ´ëÇÑ ¿¬±¸´Â ¸¹½À´Ï´Ù. ÇöÀç±îÁö ´ëºÎºÐÀÇ ¿¬±¸´Â 2³âÀ» ÁöÁöÇÏ°í ÀÖÀ¸¸ç, 1³âÀ» ÁöÁöÇÏ´Â ¿¬±¸µµ °£È¤ º» °Í °°½À´Ï´Ù. ±×·¯³ª 1³âº¸´Ù °£°ÝÀ» ÁÙÀÎ´Ù°í ´õ ÁÁÀº °á°ú¸¦ º¸Àδٴ ÀÚ·á´Â º¸Áö ¸øÇÑ °Í °°½À´Ï´Ù. °ËÁø ³»½Ã°æÀÇ ÀûÀýÇÑ °£°Ý µî °ËÁø¿¡ ´ëÇÑ key question¿¡ ´ëÇÑ °¡Àå ±ÇÀ§ÀÖ´Â ´äº¯Àº ÀÏÀü¿¡ ¼Ò°³ÇÑ 'À§¾Ï °ËÁø ±Ç°í¾È (2015)'À» Âü°íÇϽñ⠹ٶø´Ï´Ù. ÀÌ ±Ç°í¾È¿¡¼­ °ËÁø ³»½Ã°æ °£°ÝÀ» ¾ð±ÞÇÑ ºÎºÐÀ» ¿Å±â¸é ¾Æ·¡¿Í °°½À´Ï´Ù.

"Bae [42]´Â ¾Ï°ËÁøÀ¸·Î ½ÃÇàÇÑ À§³»½Ã°æ¿¡¼­ À½¼ºÀ¸·Î ³ª¿Â Çѱ¹ÀÎÀ» ´ë»óÀ¸·Î ÄÚȣƮ¸¦ ±¸ÃàÇÏ¿© À§¾Ï°ËÁøÀÇ ÀûÁ¤°£°ÝÀ» Æò°¡ÇÏ¿´´Âµ¥, À§³»½Ã°æ À½¼ºÀÚ°¡ ¾ç¼ºÀÚ·Î ÀüȯµÇ´Â ½ÃÁ¡ÀÇ Áß¾Ó°ªÀº 24°³¿ùÀ̾ú°í, Æò±Õü·ù½Ã°£(mean sojourn time, ƯÁ¤ ¾ÏÀÌ ¹ß»ýÀ» ½ÃÀÛÇÏ¿© ÀÓ»óÁõ»óÀÌ ³ªÅ¸³¯ ¶§±îÁöÀÇ ±â°£)ÀÇ 95% CI »óÀ§ °ªÀÌ 24°³¿ù ÀüÈÄ·Î ÃøÁ¤µÇ¾î À§¾Ï °ËÁøÁÖ±â·Î 24°³¿ùÀÌ ÇÕ´çÇÏ´Ù°í ÇÏ¿´´Ù[42]. ¶Ç ´Ù¸¥ ±¹³» ¿¬±¸¿¡¼­´Â 2³â À̳»¿¡ À§³»½Ã°æÀ» ¹ÞÀº °æ¿ì¿¡ À§¾Ï º´º¯ÀÇ Å©±â°¡ ÀÛ°í, Á¶±âÀ§¾ÏÀÇ ¹ß°ßÀ², À§³»½Ã°æ ÀýÁ¦¼ú·Î Ä¡·á°¡ °¡´ÉÇÑ °æ¿ì°¡ À¯ÀÇÇÏ°Ô ¸¹¾Ò´Ù°í º¸°íÇÏ¿´´Ù[18,23,24].

¿¬·É´ëº° »ç¸Á°¨¼Ò È¿°ú¸¦ º» ±¹³» ¿¬±¸¿¡¼­ À§³»½Ã°æÀº 40-49¼¼¿Í 70-79¼¼¿¡¼­´Â 35°³¿ù±îÁö, 50-69¼¼¿¡¼­´Â 48°³¿ù ÀÌÈÄ¿¡µµ Åë°èÀûÀ¸·Î À¯ÀÇÇÑ »ç¸Á ¿¹¹æÈ¿°ú°¡ °üÂûµÇ¾ú´Ù[4]. ÀϺ»ÀÇ ¿¬±¸¿¡¼­´Â, À§³»½Ã°æÀ» 3³â ÁÖ±âÀÇ Àü·«À¸·Î ½ÃÇàÇÏ´Â °æ¿ì 30%ÀÇ À§¾ÏÀ¸·Î ÀÎÇÑ »ç¸Á ¿¹¹æÈ¿°ú¸¦ º¸ÀÌ´Â °ÍÀ¸·Î Á¶»çµÇ¾ú´Ù[3]. ºñ¿ëÈ¿°ú ºÐ¼®¿¡¼­´Â ³²ÀÚ¿¡¼­´Â 50-80¼¼¿¡ ¸Å³â, ¿©¼ºÀÇ °æ¿ì 50-80¼¼¿¡ 2³â¿¡ Çѹø¾¿ À§³»½Ã°æ°Ë»ç¸¦ ¹Þ´Â Àü·«ÀÌ ºñ¿ëÈ¿°úÀûÀ¸·Î Á¶»çµÇ¾úÀ¸¸ç[41], ±¹³» ´Ù¸¥ ¿¬±¸¿¡¼­µµ ³²³à 50¼¼ºÎÅÍ 2³â ÁÖ±âÀÇ À§³»½Ã°æ °Ë»ç°¡ °¡Àå ºñ¿ëÈ¿°úÀûÀÎ °ÍÀ¸·Î Á¶»çµÇ¾ú´Ù[4]."

°³º° ±¹¹ÎÀÇ ÀÔÀå¿¡¼­´Â 1³â¿¡ 2¹ø °Ë»ç¸¦ ¹ÞÀ¸¸é ´õ ÁÁÀ» °Í °°Áö¸¸, »ç½Ç ¸Å³â 2¹ø¾¿ ³»½Ã°æÀ» ¹Þ´Â °ÍÀº º¸ÅëÀÇ ÀÇÁö¸¦ °¡Áö°í ÀÖ´Â º¸ÅëÀÇ Àΰ£¿¡¼­´Â ¸Å¿ì ¾î·Á¿î ÀÏÀÔ´Ï´Ù. 1³â¿¡ 2¹ø¾¿ ¸î ¹ø °Ë»ç¹Þ´Ùº¸¸é ÁöÃÄ ¾²·¯Áö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¸î ¹øÀÇ ÀæÀº °Ë»ç ÈÄ °Ë»ç ÀÚü¿¡ ȸÀÇ°¡ »ý°Ü ¾Æ¿¹ Àå±â°£ °Ë»ç¸¦ ¹ÞÁö ¾Ê°í Áö³»´Â ºÐµéÀÌ ¸¹½À´Ï´Ù. ±×·¯´Ù°¡ ÁøÇ༺À§¾ÏÀ¸·Î ¹ß°ßµÇ±âµµ ÇÕ´Ï´Ù. ¾ÈŸ±î¿î ÀÏÀÌÁö¿ä. ÀÌ·¡Àú·¡ °ËÁø °£°Ý °áÁ¤Àº ¾î·Á¿î ÁÖÁ¦ÀÔ´Ï´Ù. ³ÃöÇÑ ³í¸®·Î ÇØ°áÇÒ ¼ö ¾ø´Â À̽´ÀÌ°í Àΰ£ÀÇ ½É¸®±îÁö °í·ÁÇØ¾ß Çϱ⠶§¹®ÀÔ´Ï´Ù. ±×·¡¼­ Àú´Â "Àå±âÀûÀÌ°í Á¤±âÀûÀÎ ÃßÀû°Ë»ç°¡ ¿ÀÈ÷·Á À¯¸®ÇÑ °æ¿ì°¡ ÀÖ´Ù"´Â Á¡À» °­Á¶ÇÏ°í ÀÖ½À´Ï´Ù. ¾Æ·¡¿Í °°Àº ½Ã³ª¸®¿ÀÀÔ´Ï´Ù.

* Âü°í: EndoTODAY °Ç°­°ËÁø ³»½Ã°æ °£°Ý

Á¤ºÎ¿¡¼­´Â 2³â¿¡ Çѹø °ËÁøÀ» ±ÇÇÏ°í Àִµ¥, ȸ»ç¿¡¼­ Á÷¿ø º¹Áö Â÷¿ø¿¡¼­ ¹«·á·Î °Ë»ç¸¦ Á¦°øÇÏ´Â °æ¿ìµµ ¸¹°í, ¼Ó¾²¸± ¶§¸¶´Ù °Ë»ç¸¦ ¹Þ´Â ȯÀÚµµ ÀÖ½À´Ï´Ù. 1³â¿¡ ¸î ¹ø ³»½Ã°æ ¹Þ´Â ȯÀÚ¸¦ Á¾Á¾ ¸¸³³´Ï´Ù. ¾îÀ̾ø´Â ÀÏ·Î »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. ³»½Ã°æ ¼ö°¡°¡ ³Ê¹« ³·¾Æ¼­ ³»½Ã°æ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Áö³ªÄ¡°Ô ÁÁÀº °ÍÀÌ ÇÑ°¡Áö ¿øÀÎÀ̱⵵ ÇÕ´Ï´Ù. Àΰ£ÀÇ ¿å¸Á¿¡´Â ³¡ÀÌ ¾øÀ¸¹Ç·Î ¸·À» ¹æµµ´Â ¾ø½À´Ï´Ù¸¸... ¿©ÇÏÆ° ¹Ì±¹Àº ³Ê¹« ºñ½Î¼­ Å»ÀÌ°í Çѱ¹Àº ³Ê¹« ½Î¼­ Å»ÀÔ´Ï´Ù.

¼±»ý´ÔÀÇ Áú¹®¿¡ ÃæºÐÇÑ ´äÀÌ µÇ¾ú´ÂÁö ¸ð¸£°Ú½À´Ï´Ù. ´õ ±Ã±ÝÇÑ Á¡ÀÌ ÀÖÀ¸¸é ¾ðÁ¦µçÁö ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù.

[2017-8-21. ¹Ì±¹ ¼±»ý´Ô ´äº¯]

Hi, Dr. ÀÌÁØÇà;

ÂüÀ¸·Î µµ¿òµÇ´Â data, ½ÇÁ¦·Î ºÎµúÈ÷´Â on the spot data... informativeÇϸ鼭 entertaining ÇÏ¿´À¾´Ï´Ù, °¨»çÇÕ´Ï´Ù.


[2017-8-25. ¾Öµ¶ÀÚ ÆíÁö]

1950³â´ë ÀÌÈÄ¿¡ À§»ý»óÅ°¡ ÁÁ¾ÆÁö¸é¼­ À§¾ÏÀÇ ¹ß»ý·üÀº ¹Ì±¹À» ºñ·ÔÇÑ ´ëºÎºÐÀÇ ±¹°¡µé¿¡¼­´Â 80% ÀüÈÄ·Î °¨¼ÒÇß´Ù°í ÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ±Þ°ÝÇÑ °¨¼Ò¿¡µµ ºÒ±¸ÇÏ°í À¯µ¶ Çѱ¹°ú ÀϺ»¸¸ Áõ°¡ÇßÀ¸¸ç, ±× ¿ÍÁß¿¡µµ ´ë¸¸Àº °¨¼ÒÇß½À´Ï´Ù (J Formos Med Assoc. 2016).

[2017-8-26. ÀÌÁØÇà ´äº¯]

ÁÁÀº ÀÚ·á °¨»çÇÕ´Ï´Ù.

À§¾Ï °ËÁø ³»½Ã°æÀº À§¾Ï ¹ß»ýÀ» ÁÙÀÌÁö ¾Ê½À´Ï´Ù. À§¾Ï »ç¸Á·üÀ» ÁÙÀÏ »ÓÀÔ´Ï´Ù.

À§¾Ï °ËÁø ³»½Ã°æÀº less invasive treatment·Î Ä¡·áÇÒ ¼ö Àִ ȯÀÚÀÇ ºñÀ²À» ³ôÀδٰųª À§¾ÏÀ¸·Î ÀÎÇÑ »ç¸Á·üÀ» ³·Ãß´Â °ÍÀº ÀÎÁ¤ÇÏÁö¸¸, ¹ß»ý·üÀ» ³·ÃßÁö´Â ¾Ê½À´Ï´Ù. ´Ù¼öÀÇ ¼±Á¾À» ¹ß°ßÇÏ°í Ä¡·áÇϸé À§¾Ï ¹ß»ýÀ» ÁÙÀÏÁö ¸ð¸£°ÚÀ¸³ª ¾ÆÁ÷ ±Ù°Å´Â ºÎÁ·ÇÕ´Ï´Ù. ¹Ý¸é ´ëÀå¾Ï °ËÁø ³»½Ã°æÀº ´ëÀå¾Ï ¹ß»ýÀ» ÁÙÀÔ´Ï´Ù. ´ëÀå¿¡¼­´Â adenoma-carcinoma sequence°¡ Àß Àû¿ëµÇ°í, ´ëÀå³»½Ã°æÀ» Çϸ鼭 Àü¾Ï¼º º´¼ÒÀÎ ¼±Á¾¼º ¿ëÁ¾À» ÀýÁ¦Çϱ⠶§¹®ÀÔ´Ï´Ù. ¾î´À Á¤µµ ±Ù°Åµµ ÀÖ½À´Ï´Ù.

À§¾Ï °ËÁø ³»½Ã°æÀÌ ¿ÀÈ÷·Á À§¾Ï ¹ß»ýÀ» ´Ã¸± °³¿¬¼ºÀÌ ÀÖ´Ù´Â ÁÖÀåÀ» µéÀº ¹Ù Àִµ¥ ³»½É °ø°¨ÇÏ°í ÀÖ½À´Ï´Ù. ÀÏÀü¿¡ ³íÀÇÇÑ ¹Ù¸¦ ±Û·Î ¿Å°Üº¾´Ï´Ù. (1) °ú°Å¿Í °°ÀÌ ¼Òµ¶ÀÌ ºÒÃæºÐÇÑ »óÅ¿¡¼­ ´Ù¼öÀÇ °ËÁø ³»½Ã°æÀÌ ½ÃÇàµÇ¸é Helicobacter¿Í °°Àº pathogenÀÌ ÀüÆĵǾî À§¾Ï ¹ß»ýÀ» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù. Áõ°Å´Â ¾ø½À´Ï´Ù. °¡´É¼ºÀº ³ô½À´Ï´Ù. öÀúÇÑ ¼Òµ¶Àº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. (2) °ËÁøÀ» ÅëÇÏ¿© ¹ß°ßÇÏÁö ¾Ê¾Æµµ ÁÁÀ» À§¾ÏÀ» ´Ù¼ö ¹ß°ßÇÔÀ¸·Î½á À§¾Ï ¹ß»ý·üÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¸é 10³â ÀÌÇÏÀÇ survivalÀÌ ¿¹ÃøµÇ´Â ȯÀÚ¿¡¼­ ¹ß°ßµÈ ÀÛÀº ºÐÈ­Çü Á¶±âÀ§¾Ï °°Àº °ÍÀÔ´Ï´Ù.

À§¾Ï°úÀÇ ÀüÀï¿¡¼­ ½Â¸®ÇÏ·Á¸é Á¶±â Áø´Ü¸¸À¸·Î´Â ºÎÁ·ÇÕ´Ï´Ù. ¿¹¹æÀ» À§ÇÑ ³ë·Âµµ ÇÔ²² ÁøÇàµÇ¾î¾ß ÇÕ´Ï´Ù. ÀúÀÇ Á¦¾ÈÀÔ´Ï´Ù.

1) 40¼¼ À̻󿡼­ Á¤±âÀûÀÎ À§¾Ï °ËÁø ³»½Ã°æ - Á¶°ÇÀº µÎ °¡ÁöÀÔ´Ï´Ù. (1) 10³â ÀÌÇÏÀÇ survivalÀÌ ¿¹ÃøµÇ´Â ȯÀÚ¿¡¼­ÀÇ À§¾Ï °ËÁø ³»½Ã°æÀº ±× À¯¿ë¼ºÀÌ ¸íÈ®ÇÏÁö ¾Ê½À´Ï´Ù. (2) ¿ì¸®³ª¶ó¿¡¼­ À§¾Ï °ËÁø barium studyÀÇ È¿°ú´Â ¾Æ¿¹ ¾ø°Å³ª °ÅÀÇ ¹Ì¹ÌÇϸç, À§³»½Ã°æº¸´Ù´Â È®½ÇÈ÷ ¶³¾îÁý´Ï´Ù. À§¾Ï °ËÁø¿¡¼­ barium study´Â ºüÁ®¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù.

2) ³»½Ã°æ Áú°ü¸® - ¼¼ °¡Áö ¹æÇâÀÔ´Ï´Ù. (1) õõÈ÷ ÀÚ¼¼È÷ °Ë»çÇÒ ¼ö ÀÖµµ·Ï ÀûÀýÇÑ ¼ö°¡ º¸Àå, (2) ³»½Ã°æ ÀÇ»çÀÇ ÃæºÐÇÑ ±³À°. ¾ÕÀ¸·Î´Â ±³À°À» ¹ÞÁö ¾ÊÀº »óÅ¿¡¼­ »õ·Î ³»½Ã°æÀ» Àâ´Â Àǻ簡 ³ª¿Í¼­´Â ¾ÈµË´Ï´Ù. (3) ³»½Ã°æ ¼Òµ¶ °ü¸®

3) À§¾Ï ¿¹¹æÀ» À§ÇÑ Helicobacter Á¦±ÕÄ¡·á - ÇöÀç´Â ±ÔÁ¤ ¹ÛÀÌÁö¸¸ Àû¾îµµ optional ÇÏ°Ô Á¦±ÕÄ¡·á¸¦ ÇÒ ¼ö ÀÖµµ·Ï ½ÉÆò¿ø ±ÔÁ¤ÀÌ ¼öÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù. ¾ÆÁÖ ±ÞÇÑ ÀÏÀÔ´Ï´Ù.

4) ½Ä»ýÈ° °³¼± Ä·ÆäÀÎ - ³Ê¹« ÀÚ±ØÀûÀÎ À½½Ä, ³Ê¹« § À½½Ä, ź À½½ÄÀ» ÇÇÇÏ°í ±ÕÇüÀâÈù ºÎµå·´°í ¾ß䳪 ä¼Ò°¡ ¸¹Àº À½½ÄÀ» µéµµ·Ï È«º¸È°µ¿À» ÇØ¾ß ÇÒ °Í °°½À´Ï´Ù. ÀÚ±ØÀûÀÎ °ÍÀ» ÁÁ¾ÆÇÏ´Â ¼¼»ó¿¡¼­ À½½Äµµ Á¡Â÷ ÀÚ±ØÀûÀ¸·Î ¹Ù²î°í ÀÖ½À´Ï´Ù. ¾ÈŸ±õ½À´Ï´Ù.


[2018-2-28] ¾Ï¿¡ Àß °É¸®´Â üÁú?


[2020-11-13. ¾Öµ¶ÀÚ ÆíÁö]

¿äÁò Äڷγª19¶§¹®¿¡ ¹Ì·ïÁø ³»½Ã°æ °Ë»ç°¡ ÇѲ¨¹ø¿¡ ¹Ð·Áµé¸é¼­ Á¤¸»...¿ª´ë±ÞÀ¸·Î Èûµç ½Ã±â°¡ À̾îÁö°í Àִµ¥¿ä.. ¸öÀÌ ³Ê¹« Ä¡Ãļ­ ÀÚÄ© ±ôºý Á¤½Å ¸Û ¶§¸®°í °Ë»çÇÏ´Ù°¡ Áß¿äÇÑ °Í ³õÄ¥±îºÁ ºÒ¾ÈÇؼ­ Ä«ÆäÀÎÀ» µéÀ̺ξ °¢¼º »óÅ À¯ÁöÇϸ鼭 Á¤¸» ¹ö.Ƽ.°í. ÀÖ´Â ÁßÀε¥... ±ÞÇصµ ±¸¼®±¸¼® Àß »ìÆ캸°í º´º¯ ¾È³õÄ¡·Á°í ³ë·ÂÇÕ´Ï´Ù¸¸, 'Áö¿ÁÀÇ °ËÁøö'¿¡ Áß°£Áß°£ ¼û¾îÀÖ´Ù ³ª¿À´Â EGC¶û ±âŸ ÀÇ·ÚÇؾßÇÒ ÄÉÀ̽ºµé ¶§¹®¿¡ °Ë»çÇϸ鼭µµ ÇÑÆíÀ¸·Î´Â ¹º°¡ ÂòÂòÇÑ ±âºÐÀ» Áö¿ï¼ö°¡ ¾ø³×¿ä... ü·ÂÀûÀ¸·Î ÁöÃÄÀÖ´Ùº¸¸é Ä«ÆäÀÎ Åõ¿©°ú Á¦ ÀÇÁö¸¸À¸·Î ÄÁÆ®·Ñ ¾ÈµÇ´Â ºÎºÐÀÌ °¡²û À־¿ä..


[References]

1) EndoTODAY ¾Ï°ËÁø

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.